HLA-B and Stevens-Johnson syndrome: The FDA added a Boxed Warning to its prescribing information requiring pre-treatment genetic testing in certain populations for HLA-B*15:02 due to Stevens-Johnson syndrome/Toxic Epidermal Necrolysis (SJS/TEN) risks.